EasyBlog

This is some blog description about this site

AntibioTx Strengthens Management Team with CFO and VP of Commercialization

COPENHAGEN, APRIL 02, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Morten Boesen as CFO and Mads Jellingso as VP of Commercialization

Dr. Rasmus Toft-Kehler, CEO and Co-founder commented “Strengthening our management team is critical for the company’s continued development and long-term success. What is common for Morten Boesen and Mads Jellingso is that they bring important experience and expertise from globally leading institutions within their respective fields. I am excited that they have decided to join our team at AntibioTx to support the next stage of our venture”.

Morten Boesen will take on the role as Chief Financial Officer, starting from April 1, 2018. Since 2011, Mr. Boesen has worked with EQT, the leading private equity fund in the Nordics, initially as an investment manager and subsequently as an executive director in the EQT-owned global retailer, Tiger. Prior to that, Mr. Boesen worked as a management consultant with McKinsey & Company, in the M&A advisory of Nordea Bank, and in the finance department of Novozymes, the world leader in industrial biotechnology. Mr. Boesen holds a M.Sc. in Finance and Accounting from Copenhagen Business School.

Mads Jellingso will take on the role of Vice President of Commercialization. Mr. Jellingso joins AntibioTx from Novo Nordisk, where he most recently specialized in global market access and innovative contracting. Mr. Jellingso also has experience from the legal affairs and finance departments of Novo Nordisk, and prior to that he worked as a management consultant with McKinsey & Company and management advisor in Nordea Market. Mr. Jellingso holds a M.Sc. in Economics from University of Copenhagen.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

 

FDA Approves IND to Conduct Clinical Studies with ...
AntibioTx Announces Positive Data Supporting the S...

News